Blue Owl Capital Holdings LP Lowers Stock Holdings in Compass Pathways PLC Sponsored ADR $CMPS

Blue Owl Capital Holdings LP decreased its position in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 22.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 469,914 shares of the company’s stock after selling 135,000 shares during the period. Blue Owl Capital Holdings LP’s holdings in Compass Pathways were worth $3,242,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of CMPS. Jefferies Financial Group Inc. purchased a new position in shares of Compass Pathways during the 3rd quarter valued at $7,890,000. Nantahala Capital Management LLC lifted its stake in shares of Compass Pathways by 47.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock valued at $11,704,000 after buying an additional 1,350,698 shares in the last quarter. Ameriprise Financial Inc. purchased a new position in shares of Compass Pathways during the 3rd quarter valued at $6,926,000. Two Sigma Investments LP lifted its stake in shares of Compass Pathways by 838.4% during the 3rd quarter. Two Sigma Investments LP now owns 1,075,277 shares of the company’s stock valued at $6,161,000 after buying an additional 960,685 shares in the last quarter. Finally, Eagle Health Investments LP purchased a new position in shares of Compass Pathways during the 3rd quarter valued at $5,360,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

Compass Pathways Price Performance

CMPS opened at $11.81 on Monday. The firm has a 50-day simple moving average of $7.63 and a two-hundred day simple moving average of $6.91. Compass Pathways PLC Sponsored ADR has a 52 week low of $2.25 and a 52 week high of $12.24. The company has a market capitalization of $1.59 billion, a PE ratio of -3.75 and a beta of 2.39. The company has a quick ratio of 3.32, a current ratio of 3.32 and a debt-to-equity ratio of 0.15.

Compass Pathways (NASDAQ:CMPS) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. Analysts forecast that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on CMPS shares. Maxim Group lifted their target price on shares of Compass Pathways from $12.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, May 15th. HC Wainwright restated a “buy” rating on shares of Compass Pathways in a research note on Friday. Royal Bank Of Canada lifted their target price on shares of Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a research note on Thursday, May 14th. Compass Point set a $15.00 target price on shares of Compass Pathways in a research note on Thursday, February 12th. Finally, B. Riley Financial initiated coverage on shares of Compass Pathways in a research note on Friday, April 24th. They set a “buy” rating and a $17.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.58.

Compass Pathways Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.